ENLV
Enlivex Therapeutics Ltd
NASDAQ: ENLV · HEALTHCARE · BIOTECHNOLOGY
$1.78
-29.92% today
Updated 2026-10-30
Market cap
$4.03M
P/E ratio
0.00
P/S ratio
—
EPS (TTM)
$436.53
Dividend yield
—
52W range
$0 – $20
Volume
1.2M
WallStSmart proprietary scores
36
out of 100
Grade: D
Sell
Investment rating
4.3
Growth
C8.5
Quality
A5.0
Profitability
C+5.0
Valuation
C+3/9
Piotroski F-Score
Weak
4.5
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →247 stocks currently score above 75
Price targets
Analyst target
$80.00
+4394.38%
12-Month target
$1.02
-42.70%
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Altman Z 4.50 — safe zone
+ ROE 126.20% — strong efficiency
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-5.47M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Net income | $-31.06M | $-29.07M | $-15.01M | $1.24B | $1.89B |
| EPS | — | — | — | — | $436.53 |
| Free cash flow | $-32.08M | $-23.76M | $-13.11M | $-10.48M | $-5.47M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Enlivex Therapeutics Ltd trades at $1.78. Our Smart Value Score of 36/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 4.50, it sits in the safe zone.
Frequently asked questions
What is Enlivex Therapeutics Ltd's stock price?
Enlivex Therapeutics Ltd (ENLV) trades at $1.78.
Is Enlivex Therapeutics Ltd overvalued?
Enlivex Therapeutics Ltd carries a Smart Value Score of 36/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Enlivex Therapeutics Ltd (ENLV)?
The 12-month analyst consensus target is $80.00, about 4394.4% above the current $1.78. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Enlivex Therapeutics Ltd's Altman Z-Score is 4.50, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE126.20%
Beta1.41
50D MA$0.87
200D MA$9.17
Shares out0.02B
Float0.01B
Short ratio—
Avg volume1.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—